Aducanumab Phase 4 Real-World Observational Study Announced
July 29th 2021The ICARE AD-US trial is expected to enroll 6000 participants, with at least 16% of the population aimed at including those from underrepresented communities. The unrelated confirmatory phase 4 trial is still in the process of being designed.
Positive Effects of Pimavanserin for Patients With AD: Clive Ballard, MD
July 29th 2021Clive Ballard, MD, professor of age related diseases at University of Exeter, commented on the potential impact that the approval of pimavanserin would have for patients if approved for dementia-related psychosis.
Cutting Edge Care in Multiple Sclerosis: Advances in S1P Therapy
July 28th 2021Jessica L. Stulc, MD, MPH, offered an in-depth review of the latest approved therapies in the sphingosine phosphate 1 targeting class of oral medications for MS including ozanimod (Zeposia; BMS) and ponesimod (Ponvory; Janssen).
Researching Posttraumatic Headache With Cranial Neuralgias: Paul G. Mathew, MD, DNBPAS, FAAN, FAHS
July 27th 2021The assistant professor of neurology at Harvard Medical School discussed the motivation behind uncovering more about painful cranial neuralgias and their association with posttraumatic headache.
Sildenafil Shows Potential as Alzheimer Disease Preventive Therapy
July 27th 2021The therapy, already FDA-approved for individuals with pulmonary artery disease, was significantly associated with reduced likelihood of Alzheimer disease in both the 65-74 year range and those older than 75 years.
Stroke Systems of Care: Mitchell S.V. Elkind, MD, MS, MPhil
July 26th 2021Following the publication of new guidelines for the care of adults poststroke, the president of the American Heart Association commented on streamlining systems of care to manage acute stroke and foster long-term prevention.